This Is MS Multiple Sclerosis Community: Knowledge & Support

Opexa Therapeutics to Present at C.E. Unterberg, Towbin Life Sciences Investor Conference

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company involved in the development and commercialization of cell therapies, today announced that David McWilliams, Opexa’s chief executive officer, will present at the C.E. Unterberg, Towbin Life Sciences Conference on Tuesday, October 31, 2006, at 2:00 PM Eastern Time. The conference will be held at the Palace Hotel in New York City from October 30 through October 31, 2006.

Individuals may listen to a live web cast of the presentation by logging on to the Investor Relations section of Opexa’s web site www.opexatherapeutics.com a few minutes prior to start time to download any necessary software. The C.E. Unterberg, Towbin Life Sciences Conference will feature representatives from 95 emerging growth companies from biotechnology, medical technology, drug delivery and specialty pharmaceuticals sectors.

I just deleted this from the drug pipeline cause I thought you had beat me to it but I guess I will repost it.




October 31, 2006 07:00 AM Eastern Time
Opexa Therapeutics to Present at Rodman & Renshaw Eighth Annual Healthcare Conference
Rodman & Renshaw Healthcare Conference 2006
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company involved in the development and commercialization of cell therapies, today announced that its chief executive officer, David McWilliams, will present at the upcoming Rodman & Renshaw Eighth Annual Healthcare Conference. The presentation is scheduled for 9:55 AM (Eastern Time) on Tuesday, November 7, 2006. The event will be held from November 6-8, 2006 at the New York Palace Hotel in New York.

Individuals may listen to a live web cast of the presentation by logging on to the Investor Relations section of Opexa’s web site www.opexatherapeutics.com a few minutes prior to start time to download any necessary software.

The conference will feature presentations from more than 290 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. Details regarding the conference can be obtained at www.rodmanandrenshaw.com.

About Opexa Therapeutics

Opexa Therapeutics develops and commercializes cell therapies to treat several major disease areas such as MS, rheumatoid arthritis, pancreatic and cardiac conditions. Opexa has exclusive license from Baylor College of Medicine for individualized cell therapies and has initiated a Phase IIb clinical trial to evaluate effectiveness in treating MS. The Company holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences of the People's Republic of China. Opexa also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Contacts
Opexa Therapeutics, Inc.
Lynne Hohlfeld, 281-719-3421
lhohlfeld@opexatherapeutics.com
or
Investor Relations Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Bruce Voss, 310-691-7100
bvoss@lhai.com

I keep seeing reference to the Rodman & Renshaw Eighth Annual Healthcare Conference - it's more than neurology, but all the drugs companies involved in MS e.g. Acorda are attending. Biogen have still to provide details on the Phase II Rituximab RR trial and they were due to present the results at a conference - so this might be it.

I think the conference is in New York. If anyone attends, look out for a Canadian man of a certain age wearing his "Down with Biogen" T-shirt.

Ian

If you click on the above websites for Opexa's website and look at the video presentations of how the drug is proposed to work, it is very interesting. I hope they are correct in their theory, and this treatment works quite well.

_________________
Take care, Ewizabeth Previously Avonex, Rebif & Copaxone RRMS ~Tysabri, 31 infusions, ended 9/09. Starting Copaxone 12/09, waiting for Cladribine to be approved in 2010.

This presentation, which was freely available on the web, has now been converted to an easy to read and print pdf format. It's now available at http://www.msu.edu/~lyonro/Opexa06.pdf for the time being as Lyon has graciously offered to host it on the web. Hopefully, it will answer many of the same questions that keep coming up on this forum.

Enjoy, NHE